CLINICAL_TRIALS
withdrawal
· 2016-12-30
Clinical Trial Update: A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib [Phase 4]
Summary
A Phase 4 trial evaluating Crizotinib for systemic ALK-positive anaplastic large cell lymphoma has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Jun Zhu | Conditions: Systemic Anaplastic Large-Cell Lymphoma | Phase 4 | Status: WITHDRAWN